ストックスクリーナーアプリを入手
4.28
7.81%
0.31
前日終値:
$3.97
開ける：
$4.14
24時間の取引高:
76,915
Relative Volume:
0.83
時価総額：
$242.97M
収益：
-
当期純損益:
$-66.86M
株価収益率:
-3.5667
EPS:
-1.2
ネットキャッシュフロー:
$-58.82M
1週間 パフォーマンス:
+12.04%
1か月 パフォーマンス:
+17.58%
6か月 パフォーマンス:
-0.23%
1年 パフォーマンス:
+5.42%
1日の値動き範囲:
$3.97
$4.3382
1週間の範囲:
$3.85
$4.415
52週間の値動き範囲:
$2.60
$7.77
Design Therapeutics Inc Stock (DSGN) Company Profile
名前
Design Therapeutics Inc
セクター
電話
858-293-4900
住所
6005 HIDDEN VALLEY ROAD, CARLSBAD
DSGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
4.28 | 246.94M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Design Therapeutics Inc Stock (DSGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-07 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-05-04 | アップグレード | Goldman | Sell → Neutral |
| 2022-06-10 | 開始されました | Wedbush | Outperform |
| 2022-05-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-01-19 | 開始されました | Goldman | Sell |
| 2021-04-20 | 開始されました | Goldman | Neutral |
| 2021-04-20 | 開始されました | Piper Sandler | Overweight |
| 2021-04-20 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Design Therapeutics Inc (DSGN) 最新ニュース
Long term hold vs stop loss in Design Therapeutics Inc.Price Forecast Based on AI Analysis - Newser
News impact scoring models applied to Design Therapeutics Inc.Free Expert Verified Stock Trade Ideas - Newser
Backtesting results for Design Therapeutics Inc. trading strategiesFree AI Screening for Swing Trade Picks - Newser
What makes Design Therapeutics Inc. stock price move sharplyTrade Setup Builder with Custom Alerts - Newser
Using flow based indicators on Design Therapeutics Inc.Technical Reversal Setup with Risk Limits - Newser
Risk vs reward if holding onto Design Therapeutics Inc.Real Time Growth Signal with Smart Setup - Newser
How to escape a deep drawdown in Design Therapeutics Inc.Free Community Shared Smart Money Signals - Newser
Will breakout in Design Therapeutics Inc. lead to full recoveryHistorical Stock Summary and ROI Review - Newser
Technical analysis overview for Design Therapeutics Inc. stockChart-Based Entry Confirmation for Beginners - Newser
Using Bollinger Bands to evaluate Design Therapeutics Inc.Free Safe Entry Stock Watch Suggestions - Newser
What MACD and RSI say about Design Therapeutics Inc.Technical Safety Zone Pattern Recognition - Newser
Has Design Therapeutics Inc. found a price floorFree ROI Boosting Trade Opportunity Calendar - Newser
What technical models suggest about Design Therapeutics Inc.’s comebackWeekly Trend Screener with Momentum Picks - Newser
Heatmap analysis for Design Therapeutics Inc. and competitorsSmart Safety Strategy With Real Data Analysis - Newser
Design Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Swing Trading Plan With Smart Signals - Newser
Advanced analytics toolkit walkthrough for Design Therapeutics Inc.Risk-Managed Trade Alerts for Consistency - Newser
Can momentum traders help lift Design Therapeutics Inc.Free Weekly Return Pick Forecast Reports - Newser
Design Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Design Therapeutics Advances GeneTAC Programs Amid FDA Hold, Reports Q2 Financial Results - AInvest
Design Therapeutics Advances GeneTAC Programs Amid FDA Hold - TipRanks
Design Therapeutics Clinical Trial Shows Promising PK Data for Friedreich Ataxia Drug | DSGN Stock News - Stock Titan
Market reaction to Design Therapeutics Inc.’s recent newsPredictive Model for Intraday Swing Forecast - Newser
Design Therapeutics, Inc. shares rise 1.26% intraday as Cartesian Therapeutics reports strong clinical trial progress and global expansion. - AInvest
Can Conifer Holdings Inc. hit a new high this monthFree Fast Exit and Entry Strategy Guide - Newser
Trend analysis for Design Therapeutics Inc. this weekFree Capital Growth With Controlled Risk Picks - Newser
Fuchs Dystrophy Pipeline 2025: In-depth Clinical Trials - openPR.com
Measuring Design Therapeutics Inc.’s beta against major indicesPredictable Return Strategy with AI Support - Newser
What are the latest earnings results for Design Therapeutics Inc.Capitalize on momentum-driven investment opportunities - Jammu Links News
How Design Therapeutics Inc. stock performs during market volatilityRisk-Managed Strategy Based on Price Analysis - Newser
What analysts say about DiaMedica Therapeutics Inc. stockDiscover hidden gems in the stock market - Jammu Links News
How does Design Therapeutics Inc. generate profit in a changing economyBuild wealth with reliable stock picks - Jammu Links News
Design Therapeutics Inc. Stock Analysis and ForecastBuild wealth steadily with smart trading - Jammu Links News
How volatile is Design Therapeutics Inc. stock compared to the marketMaster stock selection with insider knowledge - Jammu Links News
What is the dividend policy of Design Therapeutics Inc. stockHigh-yield investments - Jammu Links News
What makes Design Therapeutics Inc. stock attractive to long term investorsLow-Risk Reversal Pattern Analysis Tracker - Newser
Design Therapeutics (DSGN) Expected to Announce Earnings on Monday - Defense World
How many analysts rate Design Therapeutics Inc. as a “Buy”Advanced Screener Alerts That Work - jammulinksnews.com
What are the technical indicators suggesting about Design Therapeutics Inc.Free Stock Insights From AI Tools - Jammu Links News
Design Therapeutics Inc (DSGN) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
3.39%
大文字化:
|
ボリューム (24 時間):